Search This Blog

Tuesday, July 9, 2019

NeoGenomics to build new facility in Florida

NeoGenomics (NASDAQ:NEO) intends to build a cancer diagnostics testing facility and new global business headquarters in Fort Myers, Florida.
The new facility is expected to open in 2021.
The 150,000-square-foot laboratory and headquarters facility will also support clinical trials for new oncology therapeutics.
The Florida Department of Economic Opportunity and Lee County have offered the following economic support:
Florida state capital investment tax credits, tax refunds and Lee County community support.
Posted by at No comments:

Cara Therapeutics initiates mid-stage Oral KORSUVA trial

Cara Therapeutics (NASDAQ:CARA) commences a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in patients with atopic dermatitis (AD).
The study will enroll approx. 240 adult subjects with AD.
The primary efficacy endpoint is the change from baseline in the weekly mean of the daily 24-hour Itch Numeric Rating Scale (I-NRS) score at Week 12 of the treatment period.
Posted by at No comments:

Sandoz extends SYMJEPI injection launch to US pharmacies

Sandoz, a Novartis (NYSE:NVS) division, announces the US retail launch of SYMJEPI (epinephrine) 0.3 mg and 0.15 mg Injections. It will be now available in local pharmacies across the nation.
SYMJEPI is a single-dose, pre-filled syringe and device combination as an alternative to epinephrine auto-injectors for the emergency treatment of allergic reactions (Type 1), including anaphylaxis, a severe reaction that can lead to death if left untreated.
Sandoz launched SYMJEPI 0.3 mg Injection in the institutional (hospital) setting earlier this year.
Posted by at No comments:

Titan Pharma up on Probuphine distribution deal with CVS

Thinly traded nano cap Titan Pharmaceuticals (NASDAQ:TTNP) is up 12% premarket on light volume in reaction to its agreement with CVS Health unit CVS Caremark for the distribution of its Probuphine (buprenorphine) implant for the treatment of opioid use disorder.
Financial terms are not disclosed.
Posted by at No comments:

Allscripts offers a new platform for health data transition

Allscripts Healthcare Solutions (NASDAQ:MDRX) announces FollowMyHealth, as a platform for existing Microsoft HealthVault users to transition and share their health data with family, friends or their home care team when required.
FollowMyHealth offers an option to export their existing data and continue tracking their health online or through its mobile apps. HealthVault will be retired on November 20.
Posted by at No comments:

Bayer approached Elanco about possible deal

Bloomberg reports that Bayer (OTCPK:BAYRY +1.4%) recently contacted Elanco Animal Health (ELAN +2.1%) about a possible deal.
Bayer’s animal health unit generated €421M (+1.7%) in sales in Q1, representing 3.2% of the company’s overall revenues.
Elanco, spun out of Eli Lilly last year, generated $731M in sales in Q1.
Update: According to the Financial Post, the companies are discussing a merger. Bayer’s motivation is raising cash after its $63B takeout of Monsanto.
Posted by at No comments:

Pulmatrix up on advancement of mid-stage Pulmazole study

Nano cap Pulmatrix (PULM +4.4%) is up on below-average volume following its announcement that three sites in the U.S. have been activated for its Phase 2 study of Pulmazole for the treatment of allergic bronchopulmonary aspergillosis in asthma patients.
17 of the 25 treatment sites are in the U.S., UK and Australia. The remaining eight are in India and Poland.
Posted by at No comments:
Subscribe to: Comments (Atom)